IQVIA PRIME – Eucure – Oncology Trial

People with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC) are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.

You may be eligible to participate in this study if you:

• Are at least ≥18 of age
• Have at least 1 unidimensional measurable disease
• Have histologically or cytologically confirmed unresectable or metastatic melanoma and pancreatic ductal adenocarcinoma

You may not participate in this study if you:

• Have another active invasive malignancy within 5 years
• Have a known or suspected history of an autoimmune disorder
• Have severe cardiovascular disease
• Have received any anticancer therapy or investigational agent within 4 weeks
• Have received a live attenuated vaccine within 28 days
• Had major surgery within 4 weeks prior to study
• Have an active infection of human immunodeficiency virus, hepatitis B, hepatitis C, or Covid-19
• Are pregnant, lactating or planning to become pregnant

Contact Information
Shana Haynes-Harp, Study Coordinator
Phone: (347)-389-4390